Skip to main content
Top
Published in: Applied Health Economics and Health Policy 4/2013

01-08-2013 | Original Research Article

Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population

Authors: David S. Geldmacher, Noam Y. Kirson, Howard G. Birnbaum, Sara Eapen, Evan Kantor, Alice Kate Cummings, Vijay N. Joish

Published in: Applied Health Economics and Health Policy | Issue 4/2013

Login to get access

Abstract

Background and Objectives

Prior research has documented that Alzheimer’s disease (AD) is associated with increased costs from comorbid conditions. However, little is known about medical resource utilization and costs among AD patients prior to the onset of cognitive symptoms. This study estimates excess acute care costs among Medicaid AD patients in the year prior to diagnosis.

Study Design

Administrative claims data for New Jersey Medicaid patients over the period 1997–2010 were retrospectively analyzed. The study focused on non-institutionalized AD patients and examined their medical costs compared with matched controls with no dementia over the 12 months prior to their preliminary diagnosis. Costs reflect amounts reimbursed by Medicaid to medical service providers, reported in 2010 US dollars.

Results

The study sample included 11,536 AD patients who were matched to controls. Average age was 76 years, and 76.2 % were female. Compared with matched controls, total medical costs over the 12-month pre-index period were US$ 5,549 higher among AD patients (US$ 14,977 vs. US$ 9,428, p < 0.001), of which US$ 3,321 (p < 0.001) was due to outpatient services. Home care and medical daycare services accounted for US $1,442 (p < 0.001) of the difference. Emergency department visits and inpatient care accounted for only a small fraction of the excess costs.

Conclusions

Compared with controls, Medicaid AD patients incurred higher acute care costs in the 12 months prior to their preliminary diagnosis, suggesting room for beneficial interventions and better disease management should earlier diagnosis become possible. These findings may be especially relevant in light of new criteria facilitating earlier diagnosis of AD.
Literature
1.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev., Washington: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev., Washington: American Psychiatric Association; 2000.
2.
go back to reference Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62 (Epub 2011 Apr 21). Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62 (Epub 2011 Apr 21).
3.
go back to reference United States Preventive Services Task Force. The guide to clinical preventive services. Rockville: Agency for Healthcare Research and Quality; 2005.CrossRef United States Preventive Services Task Force. The guide to clinical preventive services. Rockville: Agency for Healthcare Research and Quality; 2005.CrossRef
4.
go back to reference Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160(19):2964–8.PubMedCrossRef Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160(19):2964–8.PubMedCrossRef
5.
go back to reference Boise L, Neal MB, Kaye J. Dementia assessment in primary care: results from a study in three managed care systems. J Gerontol A Biol Sci Med Sci. 2004;59(6):M621–6.PubMedCrossRef Boise L, Neal MB, Kaye J. Dementia assessment in primary care: results from a study in three managed care systems. J Gerontol A Biol Sci Med Sci. 2004;59(6):M621–6.PubMedCrossRef
6.
go back to reference Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc. 2005;53(2):295–8.PubMedCrossRef Magsi H, Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc. 2005;53(2):295–8.PubMedCrossRef
7.
go back to reference Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J Am Geriatr Soc. 2000;48(11):1430–4.PubMed Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J Am Geriatr Soc. 2000;48(11):1430–4.PubMed
9.
go back to reference Kiecolt-Glaser JK, Glaser R, Shuttleworth EC, et al. Chronic stress and immunity in family caregivers of Alzheimer’s disease victims. Psychosom Med. 1987;49(5):523–35. Kiecolt-Glaser JK, Glaser R, Shuttleworth EC, et al. Chronic stress and immunity in family caregivers of Alzheimer’s disease victims. Psychosom Med. 1987;49(5):523–35.
10.
go back to reference Zarit S. The hidden victims of Alzheimer’s disease: families under stress. New York: NYU Press; 1985. Zarit S. The hidden victims of Alzheimer’s disease: families under stress. New York: NYU Press; 1985.
11.
go back to reference Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46(1):130–5.PubMedCrossRef Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46(1):130–5.PubMedCrossRef
12.
go back to reference Hill JW, Futterman R, Duttagupta S, et al. Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58(1):62–70.PubMedCrossRef Hill JW, Futterman R, Duttagupta S, et al. Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58(1):62–70.PubMedCrossRef
13.
go back to reference McCarten JR, Anderson P, Kuskowski MA, et al. Changes in outpatient costs following screening and diagnosis of cognitive impairment. Alzheimers Dement. 2010;6(4 Supplement):e19. McCarten JR, Anderson P, Kuskowski MA, et al. Changes in outpatient costs following screening and diagnosis of cognitive impairment. Alzheimers Dement. 2010;6(4 Supplement):e19.
14.
go back to reference Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996;47:166–77.PubMedCrossRef Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996;47:166–77.PubMedCrossRef
15.
go back to reference Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003;51(7):937–44.PubMedCrossRef Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003;51(7):937–44.PubMedCrossRef
16.
go back to reference Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc. 2005;53(1):83–7.PubMedCrossRef Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc. 2005;53(1):83–7.PubMedCrossRef
17.
go back to reference Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009;24(5):479–88.PubMedCrossRef Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009;24(5):479–88.PubMedCrossRef
18.
go back to reference Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–15.PubMedCrossRef Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–15.PubMedCrossRef
19.
go back to reference Rascati KL, Smith MJ, Neilands T. Dealing with skewed data: an example using asthma-related costs of Medicaid clients. Clin Ther. 2001;23:481–98.PubMedCrossRef Rascati KL, Smith MJ, Neilands T. Dealing with skewed data: an example using asthma-related costs of Medicaid clients. Clin Ther. 2001;23:481–98.PubMedCrossRef
20.
go back to reference Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.CrossRef Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.CrossRef
21.
go back to reference Taylor DH Jr, Sloan FA. How much do persons with Alzheimer’s disease cost Medicare? J Am Geriatr Soc. 2000;48(6):639–46. Taylor DH Jr, Sloan FA. How much do persons with Alzheimer’s disease cost Medicare? J Am Geriatr Soc. 2000;48(6):639–46.
22.
go back to reference Harriet M, Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics. 2001;19(3):303–18.CrossRef Harriet M, Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics. 2001;19(3):303–18.CrossRef
23.
go back to reference Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147(8):1049–51.PubMed Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147(8):1049–51.PubMed
26.
go back to reference Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29.PubMedCrossRef Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29.PubMedCrossRef
27.
go back to reference Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.PubMedCrossRef Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.PubMedCrossRef
28.
go back to reference Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.PubMedCrossRef Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.PubMedCrossRef
Metadata
Title
Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
Authors
David S. Geldmacher
Noam Y. Kirson
Howard G. Birnbaum
Sara Eapen
Evan Kantor
Alice Kate Cummings
Vijay N. Joish
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 4/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0038-9

Other articles of this Issue 4/2013

Applied Health Economics and Health Policy 4/2013 Go to the issue